Form 4: United Therapeutics CEO Trades Shares

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported a series of transactions involving the exercise of stock options and the sale of common stock on June 12, 2026, executed under a Rule 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., engaged in significant stock transactions on June 12, 2026.
• These transactions included the exercise of 9,500 stock options at a price of $146.03 per share, resulting in the acquisition of 9,500 shares of common stock.
• Following the exercise, Rothblatt sold these shares in multiple trades at weighted average prices ranging from $536.82 to $546.11.
• The transactions were conducted under a pre-arranged 10b5-1 trading plan adopted on November 7, 2025, which is set to continue until the exercise of 1,734,410 stock options (expiring March 15, 2027) or December 31, 2026, whichever comes first.
• The filing details various holdings, including direct ownership of 40,513 shares and indirect beneficial ownership through trusts and a spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While significant share sales occurred, they were executed under a pre-arranged 10b5-1 plan, which is a standard and accepted practice for insider stock transactions.

Positives

• The exercise and sale of shares were executed under a pre-arranged 10b5-1 trading plan, indicating a structured and potentially pre-determined strategy for managing personal holdings.
• The weighted average sale prices were significantly higher than the exercise price, suggesting a profitable transaction for the reporting person.
• The reporting person continues to hold a substantial number of shares indirectly through various trusts and directly, indicating continued investment in the company.

Negatives

• A significant number of shares were disposed of, which could be interpreted negatively by the market if not contextualized by the 10b5-1 plan.
• The total number of shares sold across multiple transactions is substantial, although the exact total is not explicitly summed in the filing.

Risks

• The 10b5-1 plan has an expiration date of December 31, 2026, or upon exercise of all remaining options, introducing a time-bound element to future transactions.
• The plan's continuation is also contingent on the exercise of a large number of stock options, which are subject to market conditions and company performance.

Future Outlook

The 10b5-1 trading plan is active and will continue until December 31, 2026, or until 1,734,410 stock options are exercised, whichever occurs first. These options expire on March 15, 2027.

Management Comments

• The exercise of stock options and sale of resulting shares were pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected for various sales executed at weighted average prices.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing insider transactions, especially those under a 10b5-1 plan, are common in the biotechnology and pharmaceutical sectors like United Therapeutics. Such plans are designed to allow executives to buy or sell company stock at predetermined times, mitigating concerns about insider trading.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive may be scrutinized, but the 10b5-1 plan provides a framework that aims to prevent insider trading concerns.
• Employees: The transactions do not directly impact employees but reflect the executive's compensation and investment strategy.
• Management: The filing confirms the ongoing management of executive compensation and stock ownership through established plans.

Next Steps

• The 10b5-1 trading plan will continue until December 31, 2026, or until all 1,734,410 stock options are exercised.
• Further transactions may occur under the existing 10b5-1 plan, subject to its terms and conditions.

Key Dates

Keywords

Form 4, SEC Filing, United Therapeutics Corp, UTHR, Martine A. Rothblatt, Stock Options, Share Sale, 10b5-1 Plan, Insider Trading, Beneficial Ownership, Common Stock